UNSPSC 51241118: Dichlorphenamide or diclofenamide

This classification denotes a cholinergic agonist and carbonic anhydrase inhibitor with the molecular formula C6H6Cl2N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VVJ6673MHY, chemically known as 4,5-dichloro-m-benzenedisulfonamide but generally known as dichlorphenamide, which bears US NIH Compound Identifier 3038. European Medicines Agency schedules Dichlorphenamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07093MIG.

UNSPSC 51241118 Dichlorphenamide or diclofenamide is a Commodity code under which state and local governments procure generic pharmaceutical products, including carbonic anhydrase inhibitors and related ophthalmic and systemic medications, for distribution through authorized drug wholesalers to public facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, operates as a multistate cooperative vehicle that consolidates pharmaceutical purchasing for participating state agencies, counties, municipalities, and public health facilities across member states including Oregon. Vendors responding to pharmaceutical contracts under this code must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and supply products bearing specific National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations.

The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, seeking multiple awards for generic multi-source pharmaceuticals and over-the-counter products with a proposal due date of March 26, 2026 and a question cutoff of February 18, 2026. Awarded vendors must have products available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, 5 percent each on compliance with administrative fee data format requirements, electronic data interchange (EDI) capability, and agreement to a 3 percent administrative fee. All products must comply with FDA requirements, possess expiration dates of at least one year from manufacture with a minimum six-month shelf life, and be submitted with product information in designated Excel spreadsheet format converted to CSV. Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and are subject to performance penalties ranging from $200 to $1,500 per violation. The contract term is two years for new responders with optional extensions at MMCAP's discretion; incumbent vendor amendments align with existing agreement expiration dates through June 30, 2028.